Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daphné Lehalle is active.

Publication


Featured researches published by Daphné Lehalle.


Clinical Genetics | 2015

A review of craniofacial disorders caused by spliceosomal defects

Daphné Lehalle; Dagmar Wieczorek; Roseli Maria Zechi-Ceide; Maria Rita Passos-Bueno; Stanislas Lyonnet; Jeanne Amiel; Christopher T. Gordon

The spliceosome is a large ribonucleoprotein complex that removes introns from pre‐mRNA transcripts. Mutations in EFTUD2, encoding a component of the major spliceosome, have recently been identified as the cause of mandibulofacial dysostosis, Guion‐Almeida type (MFDGA), characterized by mandibulofacial dysostosis, microcephaly, external ear malformations and intellectual disability. Mutations in several other genes involved in spliceosomal function or linked aspects of mRNA processing have also recently been identified in human disorders with specific craniofacial malformations: SF3B4 in Nager syndrome, an acrofacial dysostosis (AFD); SNRPB in cerebrocostomandibular syndrome, characterized by Robin sequence and rib defects; EIF4A3 in the AFD Richieri‐Costa–Pereira syndrome, characterized by Robin sequence, median mandibular cleft and limb defects; and TXNL4A in Burn‐McKeown syndrome, involving specific craniofacial dysmorphisms. Here, we review phenotypic and molecular aspects of these syndromes. Given the apparent sensitivity of craniofacial development to defects in mRNA processing, it is possible that mutations in other proteins involved in spliceosomal function will emerge in the future as causative for related human disorders.


Human Mutation | 2014

Delineation of EFTUD2 Haploinsufficiency-Related Phenotypes Through a Series of 36 Patients

Daphné Lehalle; Christopher T. Gordon; Myriam Oufadem; Géraldine Goudefroye; Lucile Boutaud; Jean-Luc Alessandri; Neus Baena; Geneviève Baujat; Clarisse Baumann; Odile Boute-Benejean; Roseline Caumes; Charles Decaestecker; Dominique Gaillard; Alice Goldenberg; Marie Gonzales; Muriel Holder-Espinasse; Marie-Line Jacquemont; Didier Lacombe; Sylvie Manouvrier-Hanu; Sandrine Marlin; Michèle Mathieu-Dramard; Gilles Morin; Laurent Pasquier; Florence Petit; Marlène Rio; Robert Smigiel; Christel Thauvin-Robinet; Alexandre Vasiljevic; Alain Verloes; Valérie Malan

Mandibulofacial dysostosis, Guion‐Almeida type (MFDGA) is a recently delineated multiple congenital anomalies/mental retardation syndrome characterized by the association of mandibulofacial dysostosis (MFD) with external ear malformations, hearing loss, cleft palate, choanal atresia, microcephaly, intellectual disability, oesophageal atresia (OA), congenital heart defects (CHDs), and radial ray defects. MFDGA emerges as a clinically recognizable entity, long underdiagnosed due to highly variable presentations. The main differential diagnoses are CHARGE and Feingold syndromes, oculoauriculovertebral spectrum, and other MFDs. EFTUD2, located on 17q21.31, encodes a component of the major spliceosome and is disease causing in MFDGA, due to heterozygous loss‐of‐function (LoF) mutations. Here, we describe a series of 36 cases of MFDGA, including 24 previously unreported cases, and we review the literature in order to delineate the clinical spectrum ascribed to EFTUD2 LoF. MFD, external ear anomalies, and intellectual deficiency occur at a higher frequency than microcephaly. We characterize the evolution of the facial gestalt at different ages and describe novel renal and cerebral malformations. The most frequent extracranial malformation in this series is OA, followed by CHDs and skeletal abnormalities. MFDGA is probably more frequent than other syndromic MFDs such as Nager or Miller syndromes. Although the wide spectrum of malformations complicates diagnosis, characteristic facial features provide a useful handle.


Nature Genetics | 2017

Disruption of the ATXN1-CIC complex causes a spectrum of neurobehavioral phenotypes in mice and humans

Hsiang Chih Lu; Qiumin Tan; Maxime W.C. Rousseaux; Wei Wang; Ronald Richman; Ying Wooi Wan; Szu Ying Yeh; Jay M. Patel; Xiuyun Liu; Tao Lin; Yoontae Lee; John D. Fryer; Jing Han; Maria H. Chahrour; Richard H. Finnell; Yunping Lei; Maria E. Zurita-Jimenez; Priyanka Ahimaz; Kwame Anyane-Yeboa; Lionel Van Maldergem; Daphné Lehalle; Nolwenn Jean-Marçais; Anne Laure Mosca-Boidron; Julien Thevenon; Margot A. Cousin; Della E. Bro; Brendan C. Lanpher; Eric W. Klee; Nora Alexander; Matthew N. Bainbridge

Gain-of-function mutations in some genes underlie neurodegenerative conditions, whereas loss-of-function mutations in the same genes have distinct phenotypes. This appears to be the case with the protein ataxin 1 (ATXN1), which forms a transcriptional repressor complex with capicua (CIC). Gain of function of the complex leads to neurodegeneration, but ATXN1–CIC is also essential for survival. We set out to understand the functions of the ATXN1–CIC complex in the developing forebrain and found that losing this complex results in hyperactivity, impaired learning and memory, and abnormal maturation and maintenance of upper-layer cortical neurons. We also found that CIC activity in the hypothalamus and medial amygdala modulates social interactions. Informed by these neurobehavioral features in mouse mutants, we identified five individuals with de novo heterozygous truncating mutations in CIC who share similar clinical features, including intellectual disability, attention deficit/hyperactivity disorder (ADHD), and autism spectrum disorder. Our study demonstrates that loss of ATXN1–CIC complexes causes a spectrum of neurobehavioral phenotypes.


Genetics in Medicine | 2017

Molecular diagnosis of PIK3CA -related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing

Paul Kuentz; Judith St-Onge; Yannis Duffourd; Jean-Benoît Courcet; Virginie Carmignac; Thibaud Jouan; A. Sorlin; Claire Abasq-Thomas; Juliette Albuisson; Jeanne Amiel; Daniel Amram; Stéphanie Arpin; Tania Attie-Bitach; Nadia Bahi-Buisson; Sébastien Barbarot; Geneviève Baujat; Didier Bessis; Olivia Boccara; Maryse Bonnière; Odile Boute; Anne-Claire Bursztejn; Christine Chiaverini; Valérie Cormier-Daire; Christine Coubes; Bruno Delobel; Patrick Edery; Salima El Chehadeh; Christine Francannet; David Geneviève; Alice Goldenberg

Purpose:Postzygotic activating mutations of PIK3CA cause a wide range of mosaic disorders collectively referred to as PIK3CA-related overgrowth spectrum (PROS). We describe the diagnostic yield and characteristics of PIK3CA sequencing in PROS.Methods:We performed ultradeep next-generation sequencing (NGS) of PIK3CA in various tissues from 162 patients referred to our clinical laboratory and assessed diagnostic yield by phenotype and tissue tested.Results:We identified disease-causing mutations in 66.7% (108/162) of patients, with mutant allele levels as low as 1%. The diagnostic rate was higher (74%) in syndromic than in isolated cases (35.5%; P = 9.03 × 10−5). We identified 40 different mutations and found strong oncogenic mutations more frequently in patients without brain overgrowth (50.6%) than in those with brain overgrowth (15.2%; P = 0.00055). Mutant allele levels were higher in skin and overgrown tissues than in blood and buccal samples (P = 3.9 × 10−25), regardless of the phenotype.Conclusion:Our data demonstrate the value of ultradeep NGS for molecular diagnosis of PROS, highlight its substantial allelic heterogeneity, and confirm that optimal diagnosis requires fresh skin or surgical samples from affected regions. Our findings may be of value in guiding future recommendations for genetic testing in PROS and other mosaic conditions.Genet Med advance online publication 02 February 2017


American Journal of Medical Genetics Part A | 2011

Fetal Pads as a Clue to the Diagnosis of Pitt-Hopkins Syndrome

Daphné Lehalle; Charles A. Williams; Victoria M. Siu; Jill Clayton-Smith

Pitt–Hopkins syndrome (PHS) is characterized by severe mental retardation, characteristic facial features including a wide mouth and intermittent overbreathing. It is due to abnormalities of the TCF4 gene at 18q21.1 and over 50 cases have now been reported in the literature. The clinical features overlap significantly with those of Angelman, Rett, and Mowat–Wilson syndromes. We have observed prominent fetal pads as a feature in several individuals with PHS and suggested that this is a useful clinical sign which helps to distinguish PHS from other conditions in the differential diagnosis and may guide genetic testing.


Human Mutation | 2015

Mutations in SNRPB, Encoding Components of the Core Splicing Machinery, Cause Cerebro-Costo-Mandibular Syndrome

Séverine Bacrot; Mathilde Doyard; Céline Huber; Olivier Alibeu; Niklas Feldhahn; Daphné Lehalle; Didier Lacombe; Sandrine Marlin; Patrick Nitschke; Florence Petit; Marie-Paule Vazquez; Arnold Munnich; Valérie Cormier-Daire

Cerebro‐costo‐mandibular syndrome (CCMS) is a developmental disorder characterized by the association of Pierre Robin sequence and posterior rib defects. Exome sequencing and Sanger sequencing in five unrelated CCMS patients revealed five heterozygous variants in the small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB) gene. This gene includes three transcripts, namely transcripts 1 and 2, encoding components of the core spliceosomal machinery (SmB′ and SmB) and transcript 3 undergoing nonsense‐mediated mRNA decay. All variants were located in the premature termination codon (PTC)‐introducing alternative exon of transcript 3. Quantitative RT‐PCR analysis revealed a significant increase in transcript 3 levels in leukocytes of CCMS individuals compared to controls. We conclude that CCMS is due to heterozygous mutations in SNRPB, enhancing inclusion of a SNRPB PTC‐introducing alternative exon, and show that this developmental disease is caused by defects in the splicing machinery. Our finding confirms the report of SNRPB mutations in CCMS patients by Lynch et al. (2014) and further extends the clinical and molecular observations.


Genetics in Medicine | 2018

Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and/or intellectual disability: substantial interest of prospective annual reanalysis

Sophie Nambot; Julien Thevenon; Paul Kuentz; Yannis Duffourd; Emilie Tisserant; Ange-Line Bruel; Anne-Laure Mosca-Boidron; Alice Masurel-Paulet; Daphné Lehalle; Nolwenn Jean-Marçais; Mathilde Lefebvre; Pierre Vabres; Salima El Chehadeh-Djebbar; Christophe Philippe; Frederic Tran Mau-Them; Judith St-Onge; Thibaud Jouan; Martin Chevarin; Charlotte Poe; Virginie Carmignac; Antonio Vitobello; Patrick Callier; Jean-Baptiste Rivière; Laurence Faivre; Christel Thauvin-Robinet

PurposeCongenital anomalies and intellectual disability (CA/ID) are a major diagnostic challenge in medical genetics—50% of patients still have no molecular diagnosis after a long and stressful diagnostic “odyssey.” Solo clinical whole-exome sequencing (WES) was applied in our genetics center to improve diagnosis in patients with CA/ID.MethodsThis retrospective study examined 416 consecutive tests performed over 3 years to demonstrate the effectiveness of periodically reanalyzing WES data. The raw data from each nonpositive test was reanalyzed at 12 months with the most recent pipeline and in the light of new data in the literature. The results of the reanalysis for patients enrolled in the third year are not yet available.ResultsOf the 416 patients included, data for 156 without a diagnosis were reanalyzed. We obtained 24 (15.4%) additional diagnoses: 12 through the usual diagnostic process (7 new publications, 4 initially misclassified, and 1 copy-number variant), and 12 through translational research by international data sharing. The final yield of positive results was 27.9% through a strict diagnostic approach, and 2.9% through an additional research strategy.ConclusionThis article highlights the effectiveness of periodically combining diagnostic reinterpretation of clinical WES data with translational research involving data sharing for candidate genes.


European Journal of Human Genetics | 2017

Intragenic FMR1 disease-causing variants: a significant mutational mechanism leading to Fragile-X syndrome

Angélique Quartier; Hélène Poquet; Brigitte Gilbert-Dussardier; Massimiliano Rossi; Anne-Sophie Casteleyn; Vincent des Portes; Claire Feger; Paul Kuentz; Claire Redin; Julien Thevenon; Anne-Laure Mosca-Boidron; Patrick Callier; Jean Muller; Gaetan Lesca; Frédéric Huet; Véronique Geoffroy; Salima El Chehadeh; Matthieu Jung; Benoit Trojak; Stephanie Gras; Daphné Lehalle; Bernard Jost; Stéphanie Maury; Alice Masurel; Patrick Edery; Christel Thauvin-Robinet; Bénédicte Gérard; Jean-Louis Mandel; Laurence Faivre; Amélie Piton

Fragile-X syndrome (FXS) is a frequent genetic form of intellectual disability (ID). The main recurrent mutagenic mechanism causing FXS is the expansion of a CGG repeat sequence in the 5′-UTR of the FMR1 gene, therefore, routinely tested in ID patients. We report here three FMR1 intragenic pathogenic variants not affecting this sequence, identified using high-throughput sequencing (HTS): a previously reported hemizygous deletion encompassing the last exon of FMR1, too small to be detected by array-CGH and inducing decreased expression of a truncated form of FMRP protein, in three brothers with ID (family 1) and two splice variants in boys with sporadic ID: a de novo variant c.990+1G>A (family 2) and a maternally inherited c.420-8A>G variant (family 3). After clinical reevaluation, the five patients presented features consistent with FXS (mean Hagerman’s scores=15). We conducted a systematic review of all rare non-synonymous variants previously reported in FMR1 in ID patients and showed that six of them are convincing pathogenic variants. This study suggests that intragenic FMR1 variants, although much less frequent than CGG expansions, are a significant mutational mechanism leading to FXS and demonstrates the interest of HTS approaches to detect them in ID patients with a negative standard work-up.


American Journal of Medical Genetics Part A | 2017

Application of whole‐exome sequencing to unravel the molecular basis of undiagnosed syndromic congenital neutropenia with intellectual disability

Alexandra Gauthier-Vasserot; Christel Thauvin-Robinet; Ange-Line Bruel; Yannis Duffourd; Judith St-Onge; Thibaud Jouan; Jean-Baptiste Rivière; Delphine Héron; Jean Donadieu; Christine Bellanné-Chantelot; Claire Briandet; Frédéric Huet; Paul Kuentz; Daphné Lehalle; Laurence Duplomb-Jego; Elodie Gautier; Isabelle Maystadt; Lucile Pinson; Daniel Amram; Salima El Chehadeh; Judith Melki; Sophia Julia; Laurence Faivre; Julien Thevenon

Neutropenia can be qualified as congenital when of neonatal onset or when associated with extra‐hematopoietic manifestations. Overall, 30% of patients with congenital neutropenia (CN) remain without a molecular diagnosis after a multidisciplinary consultation and tedious diagnostic strategy. In the rare situations when neutropenia is identified and associated with intellectual disability (ID), there are few diagnostic hypotheses to test. This retrospective multicenter study reports on a clinically heterogeneous cohort of 10 unrelated patients with CN associated with ID and no molecular diagnosis prior to whole‐exome sequencing (WES). WES provided a diagnostic yield of 40% (4/10). The results suggested that in many cases neutropenia and syndromic manifestations could not be assigned to the same molecular alteration. Three sub‐groups of patients were highlighted: (i) severe, symptomatic chronic neutropenia, detected early in life, and related to a known mutation in the CN spectrum (ELANE); (ii) mild to moderate benign intermittent neutropenia, detected later, and associated with mutations in genes implicated in neurodevelopmental disorders (CHD2, HUWE1); and (iii) moderate to severe intermittent neutropenia as a probably undiagnosed feature of a newly reported syndrome (KAT6A). Unlike KAT6A, which seems to be associated with a syndromic form of CN, the other reported mutations may not explain the entire clinical picture. Although targeted gene sequencing can be discussed for the primary diagnosis of severe CN, we suggest that performing WES for the diagnosis of disorders associating CN with ID will not only provide the etiological diagnosis but will also pave the way towards personalized care and follow‐up.


European Journal of Human Genetics | 2016

Heterozygous deletion of the LRFN2 gene is associated with working memory deficits

Julien Thevenon; Céline Souchay; Gail K. Seabold; Inna Dygai-Cochet; Patrick Callier; Lucie Corbin; Laurence Duplomb; Christel Thauvin-Robinet; Alice Masurel-Paulet; Salima El Chehadeh; Magali Avila; Delphine Minot; Eric Guedj; Sophie Chancenotte; Marlène Bonnet; Daphné Lehalle; Ya-Xian Wang; Paul Kuentz; Frédéric Huet; Anne-Laure Mosca-Boidron; Nathalie Marle; Ronald S. Petralia; Laurence Faivre

Learning disabilities (LDs) are a clinically and genetically heterogeneous group of diseases. Array-CGH and high-throughput sequencing have dramatically expanded the number of genes implicated in isolated intellectual disabilities and LDs, highlighting the implication of neuron-specific post-mitotic transcription factors and synaptic proteins as candidate genes. We report a unique family diagnosed with autosomal dominant learning disability and a 6p21 microdeletion segregating in three patients. The 870 kb microdeletion encompassed the brain-expressed gene LRFN2, which encodes for a synaptic cell adhesion molecule. Neuropsychological assessment identified selective working memory deficits, with borderline intellectual functioning. Further investigations identified a defect in executive function, and auditory-verbal processes. These data were consistent with brain MRI and FDG-PET functional brain imaging, which, when compared with controls, revealed abnormal brain volume and hypometabolism of gray matter structures implicated in working memory. We performed electron microscopy immunogold labeling demonstrating the localization of LRFN2 at synapses of cerebellar and hippocampal rat neurons, often associated with the NR1 subunit of N-methyl-D-aspartate receptors (NMDARs). Altogether, the combined approaches imply a role for LRFN2 in LD, specifically for working memory processes and executive function. In conclusion, the identification of familial cases of clinically homogeneous endophenotypes of LD might help in both the management of patients and genetic counseling for families.

Collaboration


Dive into the Daphné Lehalle's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul Kuentz

University of Burgundy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge